SHMT2 and breast carcinoma: More importantly, SHTM2 expression was significantly down-regulated by lapatinib treatment; a higher SHTM2 expression was also observed in lapatinib-resistant breast cancer cells, indicating the effect of SHMT2 on breast cancer resistance to lapatinib.